Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
06-19 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades | |
06-18 | CARL ZEISS MEDITEC : CZM’s eye attractiveness fades |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company benefits from high valuations in earnings multiples.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 6.33B | - | ||
+6.37% | 213B | B | ||
+10.21% | 184B | B- | ||
+28.22% | 153B | B- | ||
+34.42% | 113B | A- | ||
+0.80% | 63.66B | A- | ||
+19.21% | 53.53B | B+ | ||
+0.13% | 49.11B | B+ | ||
-4.16% | 38.73B | A | ||
+2.39% | 36.26B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- AFX Stock
- 0DHC Stock
- Ratings Carl Zeiss Meditec AG